Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
University of Michigan Rogel Cancer Center
Massachusetts General Hospital
Bristol-Myers Squibb
BioNTech SE
EMD Serono
National Institutes of Health Clinical Center (CC)
TerSera Therapeutics LLC
Johannes Gutenberg University Mainz
University of Miami
Columbia University
AstraZeneca
Georgetown University